This message is sent to all Alzheimer's Association and Alzheimer's Impact Movement board members, all Alzheimer's Association staff, and volunteers and supporters of AIM and the Alzheimer's Association.
Today, we celebrate another important milestone in Alzheimer’s treatment. The U.S. Food and Drug Administration (FDA) granted traditional approval of donanemab, sold under the brand name Kisunla, for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive impairment and the mild dementia stage of Alzheimer’s disease, with confirmed amyloid plaques. This is the third FDA approval granted for an Alzheimer’s treatment that changes the underlying course of the disease. Learn more here.
This is real progress. Today’s action gives people more options and greater opportunity to have more time.
We are making an impact both globally and in communities. Whether you volunteer with us, donate or advocate for families facing dementia, our progress is only possible because of you.
Barbara Eades, of Chattanooga, Tennessee, was diagnosed with mild cognitive impairment (MCI) in 2018. She shares, “Today’s decision by the FDA is good news for those of us living with early Alzheimer’s. I was fortunate to participate in the clinical trial and receive this treatment. It has provided me an opportunity to live my life fully, for more time. I’m able to keep doing what I’m passionate about: sing, remain active in my church and spend time with my friends and family.”
Because of Barbara and the millions of people facing this devastating disease, the Alzheimer’s Association is leading the way with a comprehensive approach to helping those who need us most. The Alzheimer’s Association accelerates research, supports people and families, advances public policy, and engages volunteers and communities.
We have more reasons than ever to believe we will achieve a world without Alzheimer’s and all other dementia. Our work is not done. We won’t rest until everyone living with Alzheimer’s — at any stage — can get the diagnosis, treatment, care and support they need and deserve.
Thank you for all you do to move our mission forward. You can always find additional information at alz.org or at our 24/7 Helpline (800.272.3900).
